HONGQI EH7 and EHS7 Deliver Amazing Performance in the Media Test Drive
On October 11th, HONGQI held a new vehicle test drive event for European media in Paris, France, inviting more than ten mainstream automotive media representatives, including Agence France Presse, Le Journal de L'Auto, Auto Bild, and Motor1, to experience the excellent style of EH7 and EHS7. At the event, Mr. Liu Hongtao, the General Manager of HONGQI Overseas, introduced the HONGQI brand and the new vehicles, EH7 and EHS7. Meanwhile, Mr. Giles Taylor, the Vice President of Global Design and Chief Creative Officer of FAW Group, presented the aesthetic design of the vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241012601143/en/
HONGQI EH7 and EHS7 Deliver Amazing Performance in the Media Test Drive (Photo: Business Wire)
Several media representatives were impressed by the driving experience of the EH7 and EHS7. Equipped with an electric drive system featuring a maximum power of 455kW and a torque of 756Nm, the two new vehicles accelerate swiftly and deliver power smoothly, enabling them to easily cope with various road conditions. The suspension systems of the two new vehicles have been meticulously tuned, and the "iDCS self-adjusting continuous damping shock absorbers" can effectively filter out road vibrations. Media representatives have commented on the smoother handling they enjoy while driving these HONGQI vehicles.
Both the EH7 and EHS7 have spacious interiors and high-quality seating configurations to fully enhance ride comfort. The unique styling design and excellent interior quality of these two new models were also fully recognized by the media.
In terms of technology features, both models are equipped with an Intelligent assisted driving system and a 63-inch AR HUD. The media also got to experience the range of both models in action. The EH7 and EHS7 have class-leading long ranges of 655km and 600km respectively, for long-distance travel without any worries.
The test drive event not only provided European media with a deeper understanding of HONGQI and its latest products, but also established a solid foundation for the further development of HONGQI in the European market. In the future, HONGQI will continue to bring better traveling experiences to global consumers with excellent products and quality services.
As the Paris Motor Show 2024 approaches, HONGQI will also showcase the EH7 and EHS7 at the event and announce the opening of orders and related policies for the EH7 and EHS7 in France.
Click on the link to learn more about the HONGQI.
https://www.hongqi-auto.com/go/Mkg70tCa
View source version on businesswire.com: https://www.businesswire.com/news/home/20241012601143/en/
Contacts
China FAW Group Import & Export Co., Ltd
Lin Ding
https://www.hongqi-auto.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.hongqi-aut
o.com&esheet=54135111&newsitemid=20241012601143&lan=en-US&anchor=https%3A%2F%2Fw
ww.hongqi-auto.com&index=6&md5=885736b7372d4a7d504ef630fb5fa955
dinglin7@faw.com.cn
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics30.12.2024 07:50:00 CET | Press Release
PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizations from a broad spectrum of sectors, including academia, research institutions, hospitals, foundations, SMEs, medical technology, and pharmaceutical companies, all united by the mission to simplify, reduce the invasiveness of, and increase accessibility to blood collection through cutting-edge, patient-centered microsampling technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241229266268/en/ Follow Project-Comfort LinkedIn Page: https://www.linkedin.
Medical-Fish-Skin Company Kerecis Expands Silicone Fish-Skin Combination Product Range for Surgical and Trauma Wound with SurgiClose® Silicone27.12.2024 20:00:00 CET | Press Release
Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of SurgiClose® Silicone, which combines a fish-skin graft and silicone backing for efficient treatment of surgical and trauma wounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241227975454/en/ SurgiClose® Silicone (Photo: Business Wire) SurgiClose® Silicone is a part of the SurgiClose® product family, which is intact fish-skin intended for the management of trauma wounds and surgical wounds in the operating room. The new product is available in two variations, SurgiClose® Silicone Adhesive with borders that overlap the fish-skin underneath and SurgiClose® Silicone Standard with non-overlapping borders. “Applying Kerecis fish-skin to a surgical or trauma wound is a multi-step process that often requires supporting products such as sutures, st
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy27.12.2024 12:00:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (≥1). “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “This is the second U.S. approval for TEVIMBRA this year, underscoring its potential to address critical needs in oncology. We remain deeply grateful to the patients, clinicians, and resear
Takeda Announces Approval of HYQVIA ® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia27.12.2024 07:00:00 CET | Press Release
Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infu
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release
Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom